| European Case Law Identifier: | ECLI:EP:BA:2012:R001611.20120323 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 23 March 2012 | ||||||||
| Case number: | R 0016/11 | ||||||||
| Petition for review of: | T 1710/09 | ||||||||
| Application number: | 01201913.9 | ||||||||
| IPC class: | A61K 31/663 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Alendronate for use in the treatment of osteoporosis | ||||||||
| Applicant name: | Merck Sharp & Dohme Corp. | ||||||||
| Opponent name: | PLIVA, Farmaceutska Industrija Dionicko Drustvo + AWD.pharma GmbH & Co. KG STADA Arzneimittel AG Hexal AG + Sandoz AG Arrow International Ltd. betapharm Arzneimittel GmbH ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Gedeon Richter Plc. Generics [UK] Ltd. et al STADA Arzneimittel GmbH "Interpharm" ProduktionsgmbH BIOGARAN Tecnimede, Sociedade Tecnico-Medicinal, S.A. ACTAVIS GROUP |
||||||||
| Board: | EBA | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | New objection raised by the Board (no)- denial of the right to be heard (no)- petition for review clearly unallowable | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/r110016eu1.html
Date retrieved: 17 May 2021